Summary There is increasing evidence to indicate that 06-methyldeoxyguanosine (06-MedG) formation in DNA is a critical cytotoxic event following exposure to certain anti-tumour alkylating agents and that the DNA repair protein 06-alkylguanine-DNA alkyltransferase (ATase) can confer resistance to these agents. We recently demonstrated a wide inter-individual variation in the depletion and subsequent regeneration of ATase in human peripheral blood lymphocytes following sequential DTIC (400mg m2) and fotemustine (100mgm 2) treatment, with the nadir ATase activity occurring approximately 4h after DTIC administration. We have now measured the formation and loss of in the DNA of peripheral leucocytes of eight patients receiving this treatment regimen. 06-MedG could be detected within I h and maximal levels occurred approximately 3-5 h after DTIC administration. Following the first treatment cycle, considerable inter-individual variation was observed in the peak 06-MedG levels, with values ranging from 0.71 to 14.3 fimol of 06-MedG per mol of dG (6.41 ± 5.53, mean ± s.d.) . Inter-and intra-individual variation in the extent of 06-MedG formation was also seen in patients receiving additional treatment cycles. This may be a consequence of inter-patient differences in the capacity for metabolism of DTIC to release a methylating intermediate and could be one of the determinants of clinical response. Both the pretreatment ATase levels and the extent of ATase depletion were inversely correlated with the amount of 06-MedG formed in leucocyte DNA when expressed either as peak levels (r = -0.59 and -0.75 respectively) or as the area under the concentration-time curve (r = -0.72 and -0.73 respectively). One complete and one partial clinical response were seen, and these occurred in the two patients with the highest 06-MedG levels in the peripheral leucocyte DNA, although the true significance of this observation has yet to be established.
Dacarbazine (5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide; DTIC) is considered the single most effective chemotherapeutic agent available for the treatment of metastatic melanoma (Comis, 1976; Balch et al., 1989) . It undergoes metabolic N-demethylation to give the monomethyl triazene, 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (MTIC), which methylates cellular macromolecules including DNA. Among the 12 DNA lesions so formed, 06-methyldeoxyguanosine (06-MedG) is thought to be the principal cytotoxic product (Meer et al., 1986) . It has been shown that resistance to MTIC and related agents involves the activity of the DNA repair protein 06-alkylguanine-DNA alkyltransferase (ATase), which transfers the methyl group from 06-MedG to an internal cysteine residue in an autoinactivating, stoichiometric reaction (Hayward & Parsons, 1984; Gibson et al., 1986; Catapano et al., 1987; D'Incalci et al., 1988; Lunn & Harris, 1988; Foster et al., 1990) . The strongest evidence for the cytotoxic effects of 06-alkylguanine on DNA comes from experiments which show that the expression of a transfected prokaryotic or eukaryotic ATase cDNA in mammalian cells protects them against the toxic effects of these agents (Brennand & Margison, 1986; Kataoka et al., 1986; Samson et al., 1986; Jelinek et al., 1988; Kaina et al., 1991) .
We recently examined the levels of ATase in human peripheral lymphocytes following combination therapy with DTIC and the chloroethylating agent, fotemustine. ATase activity was depleted and the rate and extent of ATase depletion was patient, dosage and cycle dependent, with the nadir of ATase activity occurring 4-5 h after DTIC administration (Lee et al., 1991 (Lee et al., , 1993a . These findings have been attributed to autoinactivation of ATase during the repair of 06-MedG formed in lymphocyte DNA. It was also shown that fotemustine administration was not associated with ATase depletion in peripheral lymphocytes (Lee et al., 1993a) .
The present study investigates the kinetics of formation and loss of 06-MedG in total blood leucocyte DNA to explore possible relationships with changes in ATase levels in peripheral lymphocytes following DTIC administration. These factors may have important therapeutic implications, particularly in combination with the effects of administration of a nitrosourea for which drug resistance can also involve ATase activity (D'Incalci et al., 1988; Pegg, 1990 ).
Materials and methods
Patients and blood samples Details of the individuals studied are shown in Table I . Each patient received DTIC (400 mg m-2) by i.v. infusion over 10 min followed 4 h later by fotemustine (100 mg m2) given as a 30 min i.v. infusion. The treatment was repeated every 4 weeks except for patient F.E. (with brain metastasis), who received an additional treatment on day 8. Blood samples (20 ml) were collected just before therapy and at 1, 2, 3, 4, 5, 6 and 18 h after DTIC administration from eight patients in the first treatment cycle. A further five sets of blood samples were collected from four patients who returned for subsequent treatments. Each sample was divided into two universal containers (10 ml each) containing 0.5 ml of 0.5% EDTA, pH 8.0. One half was stored at -20'C prior to DNA extraction and radioimmunoassay for 06-MedG, while the second half was kept at 4°C before isolation of lymphocytes for ATase assays. Approval was given by the local ethical committee and informed consent was obtained from all patients prior to the study.
DNA isolation Blood samples (10 ml) were thawed, combined with 10 ml of lysis buffer (155 mM ammonium chloride, 10 mM potassium bicarbonate, 2 mM EDTA, pH 7.5) and allowed to stand at 4°C for 30min. Nuclei were collected by centrifugation at 625 g for 10 min at 4'C, resuspended in 1.5 ml of 75 mM sodium chloride, 24 mM EDTA, pH 7.5, and lysed by the addition of sodium dodecyl sulphate (SDS) to a final concentration of 1%. The lysate was then incubated overnight at 37°C in the presence of proteinase K (0.1 mg ml-'). The following day, 1.5 ml of phenol (saturated with 100 mM Tris-HCI, pH 8.0) was added and after shaking at room temperature for 10 min the mixture was centrifuged at 625 g for 5 min. The upper, aqueous phase was re-extracted with phenol as above and residual protein was removed from the final aqueous phase by extraction with 1. (Lee et al., 1991) .
06-Methyldeoxyguanosine analysis
The procedure used for the determination of 06-MedG in DNA has been described in detail elsewhere (Wild et al., 1983; Hall et al., 1991) and is presented here in outline only. DNA was digested enzymatically to nucleosides before ionexchange chromatography using Aminex A7 resin (BioRad, Hemel Hempstead, UK). The four major deoxynucleosides were separated from 06-MedG by this procedure and were quantified by peak area integration. The putative 06-MedGcontaining fractions and control fractions (i.e. similar volumes of buffer from a nucleoside-free region of the column elution profile) were analysed by radioimmunoassay using a monoclonal antibody to 06-MedG (Wild et al., 1983) .
The results are expressed relative to the amount of dG in the DNA sample. The lower limit of detection using these small amounts of DNA was -0.41 mol of 06-MedG per mol of dG.
Where sufficient sample remained, duplicate radioimmunoassay (RIA) determinations were performed, and these indicated an inter-assay variation which was generally < ± 20%. At values approaching the limit of detection, greater inter-assay variation was apparent, and this approached ± 35% as previously reported (Badawi et al., 1992) . Assay variation has also been monitored by inclusion of a control sample which varied from 0.072 to 0.102 pmol of 06-MedG (0.086 ± 0.010, mean ± s.d.) over a period of approximately 3 months.
Results 06-Alkylguanine-DNA alkyltransferase activity The data regarding the changes in ATase activity during combination chemotherapy with DTIC and fotemustine have been reported previously as mean values of a group of patients (Lee et al., 1993a) . Here, we present the pretreatment and nadir (i.e. the minimum level reached during therapy) lymphocyte ATase activity on an individual basis for all the patients in the present study (Table I) (Figure 1 ). The kinetics of DNA methylation was broadly similar in all cases: a post-treatment peak in 06-MedG formation occurred at 3-5 h and was followed by a decline in adduct level (Figure 1 ). However, in some cases (e.g. F.E./1, Figure la) A combined measure of 06-MedG formation and its persistence was obtained for each patient by integration of the area under the 06-MedG concentration-time curve (AUC; Figure 1 ). The values obtained are shown in Table I . Again, considerable inter-individual variation was apparent with 34-fold and 10-fold differences between the highest and lowest values for cycles 1 and 2 respectively. In general, leucocyte DNA from patients returning for subsequent courses of chemotherapy tended to be more extensively methylated (in terms of the 06-MedG AUC) than in patients receiving the first DTIC treatment (Table I) .
Relationship between lymphocyte A Tase activity and leucocyte 06-methyldeoxyguanosine formation in peripheral blood The nadir of ATase activity in peripheral lymphocytes occurred 4-5 h after DTIC administration, and this coincided with the peak of DNA methylation in the leucocytes. An inverse correlation was seen between the pretreatment ATase activity and the amount of 06-MedG formed in DNA expressed as either the maxima or the AUC (Figure 2a and c respectively) . The extent of lymphocyte ATase depletion (i.e. the difference between pretreatment and nadir ATase activity) was similarly related to the 06-MedG maxima and the AUC (Figure 2b and d respectively). On the other hand, no correlation between the nadir ATase activity level and the extent of 06-MedG formed in DNA was apparent.
Discussion
DTIC is a prodrug that requires metabolic activation to produce the methylating agent MTIC which can then react with DNA (Meer et al., 1986) . The present study demonstrates the presence of 06-MedG in the DNA of peripheral leucocytes from patients receiving combined DTIC/fotemustine therapy and hence the ability of these patients to activate DTIC.
Maximum levels of 06-MedG were observed 3-5 h after DTIC administration, and this coincided with the nadir in ATase activity in peripheral lymphocytes (Lee et al., 1993a) . Interestingly, DNA single-strand breaks occurring in peripheral blood lymphocytes are also maximal approximately 5 h after DTIC administration (Walles & Ringborg, 1991) .
In treatment cycle 1 there was an approximately 20-fold inter-individual variation in the 06-MedG maxima, which was also evident in the group of patients that went on to receive further courses of therapy ( Figure 1 and Table I ). The 06-MedG AUC gives a combined measure of the formation and persistence of 06-MedG, and these values also show large inter-individual variations, with differences of 34-fold and 10-fold for cycle 1 and subsequent cycles respectively. In some patients, an increase in 06-MedG level was seen at 18 h, and while this effect may be accounted for to some extent by experimental variation (see Materials and methods) reasons for the larger increases seen in patient F.E. (cycles 1 and 2) are unclear. However, similar changes in 7-methyldeoxyguanosine levels have been observed in leucocyte DNA from patients treated with DTIC, and this was attributed to changes in turnover rates of white blood cell subpopulations (van Delft et al., 1992) . Of the four patients returning for additional DTIC therapy, three show an increased 06-MedG AUC with respect to cycle 1. These values (I.P./2, I.P./3, G.B./2 and F.E./2) are associated with relatively low pretreatment ATase levels and form a small cluster in Figure 2c . The effect is most pronounced in F.E., an individual with brain metastases who received a second course of therapy 8 days after the initial treatment when 06-MedG was still detectable in leucocyte DNA ( Figure Ic) . Peak level 06-MedG (,umol/mol-dG) . subsequent DTIC cycles, suggesting that in some cases ATase expression does not readily recover. Clearly, the extent to which these present results can be extrapolated to tumour cells depends on the extent to which 06-MedG levels in leucocyte DNA correlate with those of target tumour DNA. Human tissues and tumours differ greatly in their levels of ATase (D'Incalci et al., 1988) , but there are indications that relationships between tissues may exist : studies in rodent models have shown that DNA methylation occurs to a broadly similar extent in most tissues following administration of methylating agents, even those requiring metabolic activation (Kleihues et al., 1976; Fong et al., 1990) , and to a similar extent in leucocyte DNA (Degan et al., 1988) .
In fact, in the present study, the kinetics of lymphocyte ATase depletion and leucocyte DNA 06-MedG accumulation does suggest concomitant effects in the two populations of cells. Following DTIC treatment, correlations were seen between the amount of 06-MedG formed in leucocyte DNA (expressed either as the peak value or the AUC) with the pretreatment lymphocyte ATase activity (Figure 2a and c) or with the extent of ATase depletion (Figure 2b and d) . Although these relationships are based on a relatively few patients, a similar trend was observed in a study of patients treated with the related drug, procarbazine (Souliotis et al., 1990) , and strong correlations between pretreatment ATase activity and both peak 06-MedG levels and 06-MedG AUC have recently been established in patients treated with l-pcarboxyl-3,3-dimethylphenyltriazene (CB10-277; Lee et al., 1993b; S.M. Lee et al. in preparation) . A similar relationship between ATase activity and the amount of 06-MedG in DNA was evident also in analyses of bladder mucosa from individuals exposed to environmental alkylating agents . The present results suggest that patients with high initial levels of ATase are therefore able to repair a greater proportion of the 06-MedG resulting from DTIC therapy, whilst the adduct accumulates in the leucocyte DNA of individuals with low pretreatment ATase levels.
Of the eight patients studied, only two (I.P. and K.R.) responded to therapy and, although 06-MedG AUC for both patients was close to the mean value, their leucocyte DNA contained the highest peak levels of 06-MedG after treatment cycle 1 (Table I ). This may reflect the need to reach a minimum threshold 06-MedG level before cell killing can occur.
In conclusion, the results reported here lend support to our earlier suggestion that the nadir lymphocyte ATase depletion observed approximately 4 h after 400 mg m2 DTIC is a consequence of DNA methylation, which is also maximal at this time. The wide individual variations in the extent of DNA methylation may result not only from differences in DNA repair capacity but also from differences in the capacity for metabolic activation, uptake and detoxification of DTIC. Use of DNA adduct measurement can therefore provide information on variations in cellular penetration, metabolic activation, distribution and clearance of methylating anti-tumour agents such as DTIC, which in combination with knowledge of ATase activity will permit the design of individualised treatment protocols with improved therapeutic benefit.
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